New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

NCT ID: NCT03502044

Last Updated: 2018-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-17

Study Completion Date

2020-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placebo controlled trial study of efficacy of Kinetic Oscillation Stimulation (KOS) in nasal cavity will be conducted in patients with myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The outcome of the treatment will be assessed with clinical evaluation of patients, cognitive tests, structural and functional MRI of the brain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurologic disease that is characterized by extreme physical and mental fatigue. Although some signs of inflammation have been reported previously in ME/CFS patients, the data have been quite limited and controversial. A recent study based on multiplex array of a Luminex system has demonstrated an immune signature of serum cytokines that is correlated with the disease severity and fatigue duration. Results from resting-state functional MRI (fMRI) studies have also demonstrated that there is a significant correlation between the degree of chronic fatigue and reduction of functional network connectivity in the brain.

The autonomic nervous system (ANS) plays an important role in the regulation of systemic inflammation. The nasal cavity has a rich innervation of cranial nerves. We have recently developed a non-invasive ANS stimulation technique, called Kinetic Oscillation Stimulation (KOS) in the nasal cavity. KOS treatment is expected to have a positive impact on systemic inflammation via the restoration of ANS homeostasis.

With this double blinded, placebo controlled, clinical trial, the efficacy of KOS treatment on ME/CFS will be assessed by clinical evaluation, multiplex immunoassay of peripheral blood samples, performance of psychomotor vigilance task, structural and functional MRI of the brains at the baseline point before KOS treatment and after the completion of KOS treatment period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myalgic Encephalomyelitis Chronic Fatigue Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blinded placebo controlled trial design during the first 8 treatments. Single blinded (patient is blinded) controlled trial design during the last 8 treatments.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Both the participants and investigator are blinded with regarding the administration of KOS or placebo treatments during the first 8 treatments.

During the following 8 treatments only the patients, not the investigator, are blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1, active KOS treatment

Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.

Group Type ACTIVE_COMPARATOR

Active Kinetic Oscillation Stimulation (KOS)

Intervention Type DEVICE

10 minutes active KOS treatment in each nasal cavity.

Arm 2, 8 inactive KOS treatments then 8 active KOS treatments

Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.

Group Type PLACEBO_COMPARATOR

Inactive Kinetic Oscillation Stimulation (KOS)

Intervention Type DEVICE

10 minutes inactive KOS treatment in each nasal cavity.

Active Kinetic Oscillation Stimulation (KOS)

Intervention Type DEVICE

10 minutes active KOS treatment in each nasal cavity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inactive Kinetic Oscillation Stimulation (KOS)

10 minutes inactive KOS treatment in each nasal cavity.

Intervention Type DEVICE

Active Kinetic Oscillation Stimulation (KOS)

10 minutes active KOS treatment in each nasal cavity.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) established by Consultant in Neurology.

Exclusion Criteria

* Any cardiovascular disease.
* Any other condition considered by the physician to render the patient unsuitable for participation in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karolinska University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tie-Qiang Li

Adjunct Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Per Julin, MD, PhD

Role: STUDY_DIRECTOR

Neurological Rehabilitation Clinic in Stora Sköndal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neurological Rehabilitation Clinic in Stora Sköndal

Stockholm, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tie-Qiang Li, MSc, PhD

Role: CONTACT

0046707374215

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Per Julin, MD, PhD

Role: primary

0046840029131

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KarolinskaUH2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.